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Introduction
============

Recent meta-analyses have raised fundamental questions regarding optimal fluid management in critically ill patients. A meta-analysis of randomized, controlled trials comparing colloid with crystalloid administration with respect to mortality did not support continued use of colloids for volume replacement in such patients \[[@B1]\]. Among randomized trials comparing albumin administration with either crystalloid or no albumin, a second meta-analysis suggested higher mortality in albumin recipients \[[@B2]\]. Numerous concerns have been voiced regarding the methodological soundness of these meta-analyses. Indeed, a subsequent meta-analysis failed to confirm an increased mortality risk with colloids \[[@B3]\]. Usage of albumin for fluid replacement has nevertheless declined in the wake of these reports \[[@B4]\]. Substitution of artificial colloid for albumin may have accounted for some of this decline.

One limitation of the meta-analyses was inclusion of numerous randomized trials from the late 1970s and early 1980s that may not have accurately reflected current practice. Most of the randomized trials analyzed were, in addition, unblinded, so the possibility of systematic bias cannot be dismissed. It should also be emphasized that meta-analyses with such limitations can be viewed as useful for generating hypotheses rather than supporting evidence-based clinical recommendations \[[@B3]\]. Notwithstanding their limitations, however, the meta-analyses have exerted an impact on clinical practice. Further randomized trials are now, arguably, needed to clarify the clinical utility of colloids, such as albumin. The foundation for such randomized trials should, furthermore, be laid by conducting appropriate preclinical research.

Underscoring the importance of appropriate rigorous pre-clinical research are the instructive cases of experimental sepsis therapy with monoclonal antibodies (mAb) against tumour necrosis factor (TNF) or endotoxin. These approaches appeared to embody sound therapeutic principles; namely, neutralizing key mediators of sepsis. The animal models employed to evaluate these therapies did not, unfortunately, adequately mimic clinical sepsis \[[@B5],[@B6],[@B7]\]. The principal preclinical study providing a basis for subsequent clinical trials of anti-TNF mAb therapy involved a baboon bacteraemia model. Baboons received a lethal dose of *Escherichia coli*, and control animals developed rapid-onset shock and organ failure, succumbing within 7 h of bacterial challenge. The model was thus based primarily upon intoxication as the relevant pathological process rather than infection, which is more characteristic of clinical sepsis. Subsequent randomized clinical trials failed to demonstrate a survival benefit of anti-TNF mAb therapy \[[@B8],[@B9]\].

The seminal animal study of anti-endotoxin therapy with mAb HA-1A involved, unlike clinical sepsis, pretreatment with the therapeutic agent and neither volume resuscitation nor adjuvant antibiotic therapy \[[@B10]\]. The preclinical evidence was nevertheless judged adequate to justify the initiation of clinical trials. In a double-blind, randomized clinical trial of 543 sepsis patients, no overall difference in survival could be demonstrated, although *post hoc* subgroup analysis suggested mortality reduction in patients with gram-negative bacteraemia receiving HA-1A \[[@B11]\]. A second, larger-scale, double-blind, randomized clinical trial was commenced. Prior to publication of its results, however, findings were reported from a randomized study in a canine model of gram-negative septic shock \[[@B12]\]. The canine model was clinically relevant by the criteria that the animals received aggressive fluid resuscitation as well as antibiotics and that HA-1A was administered subsequent to bacterial challenge; in this model, HA-1A actually decreased survival. The larger-scale clinical trial was reported thereafter. This larger trial, which involved 2199 patients and 603 investigators at 513 community and university-affiliated hospitals in the United States, failed to provide evidence supporting the use of HA-1A for treatment of sepsis \[[@B13]\].

The costly and disappointing failed sepsis clinical trials suggest that there may be more risk-averse and cost-effective approaches to be taken in the overall process of preclinical and clinical research by which therapeutics are evaluated. A proposal is presented in this paper that could reduce the overall risks and attendant costs of developing therapeutics for the critical care environment. The proposal calls for an alternative to the conventional pathway for preclinical research (Figure [1](#F1){ref-type="fig"}). First, developers of therapeutics should assume a leadership role in articulating hypotheses and challenging independent preclinical investigators to design and conduct rigorous randomized studies addressing the hypotheses in animal models that, as faithfully as possible, reproduce the clinical condition of interest. All available preclinical data, including the results of the randomized animal trials, should then be subjected to standard \'critical appraisal\', which might include meta-analysis of the available animal studies as appropriate. Initiation of large-scale clinical trials should await the completion of this analysis.

![Conventional and proposed alternative pathway for preclinical research, and costs associated with various phases in the development of therapeutics based on the estimates of Drews and Ryser \[[@B16]\].](cc970-1){#F1}

Elements of an alternative pathway
==================================

Animal studies can serve an array of purposes and have conventionally been employed to evaluate the pharmacology, toxicology and mechanisms of action for therapeutics, as well as providing insights into *in vivo* efficacy and safety (Figure [1](#F1){ref-type="fig"}). Studies of this type will always continue to play a role in therapeutics development. Animal model studies can and should nevertheless also be designed to yield reliable data addressing specific hypotheses regarding clinical utility for particular indications. The design of animal studies may unfortunately be driven by the research interests of independent preclinical investigators, often using previously established animal models that may not be adequately tailored to mimic accurately a clinical condition of interest. Insufficient emphasis is thus placed on rigorous testing of hypotheses related to clinical utility in this approach. An undesirable byproduct of primarily investigator-driven research is lack of adequate data in the literature bearing on the clinical potential of therapies under development. This byproduct problem could be rectified, at least in part, by greater exercise of leadership on the part of therapeutics developers.

These developers should take the responsibility to enunciate the explicit hypotheses that would need to be addressed in determining the worthiness of therapeutics to advance into clinical trials. Therapeutics developers should challenge independent preclinical investigators to design and conduct animal studies that rigorously test these hypotheses, in clinically relevant models. The familiar and well-established \'request for proposals\' (RFP) could be used to implement this approach. The RFP would clearly specify the hypotheses to be tested, and would typically appear in medical journals and stipulate a specific time period during which competitive proposals responsive to the RFP might be submitted. Competition in addressing a clearly defined and clinically relevant goal can be expected to elicit the full creativity and resourcefulness of interested preclinical investigators in identifying or devising suitable animal models and designing appropriate studies. This competitive process is likely to culminate in high-quality research proposals. The selection of the best proposals for funding might then be accomplished via peer review, using an advisory panel of experts in the field. The RFP might also allow investigators to propose additional research programme components addressing topics of interest such as mechanisms of action. The needs of the therapeutics developer and the research interests of the independent preclinical investigator might thus be simultaneously accommodated.

A major advantage of this hypothesis-driven competitive research approach is that preclinical investigators will be challenged both to formulate imaginative and sound proposals and, as necessary, to develop improved or novel animal models to replicate the clinical condition of interest. Collaboration with veterinarians may be of value in this regard. Ongoing research makes it clear that animal models can be improved and that novel models can arise, in some instances with the aid of emerging technology. Recently, for example, an improved clinically relevant sepsis model in the conscious rat has been described \[[@B7]\]. Creation of interleukin-10-deficient knockout mice by genetic engineering has additionally provided a new model of intestinal inflammation \[[@B14]\]. It should also be feasible, with the collaboration of veterinarians, to identify models representative of other clinical conditions such as haemorrhagic shock or reperfusion injury.

Critical appraisal of animal model studies
==========================================

All available preclinical data, including those generated by the randomized animal model studies, should be subjected to critical appraisal before large-scale clinical trials commence. An approach for critically appraising animal model studies of sepsis has been delineated \[[@B15]\]. This approach is summarized in Table [1](#T1){ref-type="table"} and calls for both the condition of interest, such as sepsis, and the therapeutic intervention to be defined, and proceeds to address a series of key questions. Are the study results valid? Was the study blinded? Was it randomized? What were the results? Were the data subjected to appropriate statistical analysis? Was the study adequately statistically powered to answer the questions being posed? What is the relevance of the animal data to the design and anticipated results of future human studies? Finally, the strength and quality of all the available preclinical evidence need to be taken into account as a basis for recommendations regarding clinical trials to be undertaken.

###### 

Critical appraisal of animal model studies

  -----------------------------------------------------------------
  Study selection
   Indication (eg sepsis)
   Category
    Pathophysiology
    Therapy
    Other
  Study assessment
   Validity of results
    Randomization
    Accounting for all experimental subjects
    Blinding
    Comparability of groups at baseline
    Lack of confounders
   Specific findings
    Effect size
    Precision
   Generalizability to corresponding clinical indication
    Clinical relevance of animal model
    Supportive therapies similar to those in the clinical setting
    Consideration of intercurrent illness
    Species specificity of the model
    Potential cost-effectiveness
  Evidence-based recommendations
   Strength of evidence
   Quality of evidence
  -----------------------------------------------------------------

This type of critical appraisal should be routinely incorporated in the preclinical evaluation of therapeutic modalities, including resuscitation fluids. One obvious benefit would be to avoid misallocation of resources to support unfruitful clinical trials. In this regard, all participants in the health-care system have a stake in seeing that only clearly promising clinical trials are conducted, since the costs of failed trials will ultimately be born by the overall healthcare system and not solely by the developers of therapies. All participants would, furthermore, benefit from lowering the overall costs associated with developing therapeutics, currently estimated at US\$500 million \[[@B16]\]. This very high typical development cost sharply restricts the range of therapeutics that meet the criteria for commercial feasibility based on standard discounted cash flow rate of return financial models \[[@B16]\]. Numerous promising therapeutics remain undeveloped, notwithstanding clinical need. Rigorous animal studies in clinically relevant models in conjunction with critical appraisal of all available preclinical evidence might, at modest incremental cost, avoid the massive waste of resources entailed in failed large-scale clinical trials and thus contribute to lower overall development costs for therapeutics.

Meta-analysis of animal studies
===============================

One of the important tools for critical appraisal is meta-analysis, which emerged in the 1990s as a major approach for fully capitalizing on the wealth of data generated by clinical trials, especially those of relatively small scale. Meta-analysis is a quantitative form of systematic review employing statistical methods to combine and summarize the results of multiple studies \[[@B17]\]. The methodology of meta-analysis is presented in Table [2](#T2){ref-type="table"}. Meta-analyses, typically applied to the results of randomized clinical trials, also increasingly address the findings of observational clinical studies \[[@B18]\]. Preclinical data, frequently derived from numerous small-scale animal studies, would also be an appropriate subject for meta-analysis, which might reveal overall trends not evident in small studies affording, individually, only limited statistical power and yielding, collectively, sometimes apparently inconsistent results.

###### 

Methodology of meta-analysis

  -------------------------------------------------------------------
  Protocol development
   Definition of population, intervention and outcomes
   Specification of data sources and selection criteria
  Search strategy
   Adequate comprehensiveness
   Sources and techniques
   Language restrictions
  Study selection
   *A priori* criteria
   Justification of exclusions
  Methodologic quality assessment
   Basis for inclusion, explanation of heterogeneity or sensitivity
    analyses
   Minimization of bias
   Quality scoring system
  Data extraction
   Specification of data to be extracted
   Avoidance of bias
   Inclusion of all relevant data
  Analysis
   Appropriate model (fixed versus random effects)
   Effect size (eg relative risk, odds ratio, risk difference)
   Precision (confidence intervals)
   Evaluation of heterogeneity
   Subgroup analyses
   Sensitivity analyses
  -------------------------------------------------------------------

Although animal data have been much less frequently subjected to meta-analysis than clinical data, the feasibility of animal study meta-analysis has been demonstrated in a variety of investigations. For instance, meta-analysis has been reported of rodent studies on dietary fat intake in relation to the occurrence of mammary tumours \[[@B19],[@B20]\]. Meta-analytic approaches to animal carcinogenicity experiments have also been described \[[@B21],[@B22]\]. Two meta-analytic investigations have encompassed both animal and human data. In one, separate meta-analyses of 41 rat studies and 17 clinical trials each revealed a significant association between proteinuria and glomerulosclerosis \[[@B23]\]. In the other investigation, separate meta-analyses of four rat and five human studies were conducted to model the relationship between arterial blood toluene levels and behavioural responses \[[@B24]\]. Interestingly, in a meta-analysis on the accuracy of dimercaptosuccinic acid scintigraphy for the diagnosis of acute pyelonephritis, it was necessary to focus on animal studies because nephrectomy for histological examination in patients is considered unethical \[[@B25]\].

Animal study meta-analyses to date have underscored the importance of key methodological issues that are also routinely addressed in meta-analyses of human trials. Meta-analyses of animal data have thus included consideration of between-study heterogeneity \[[@B26]\], sensitivity analyses as appropriate \[[@B27]\] and evaluation of included study quality \[[@B28]\].

There are clearly no conceptual barriers to meta-analysis of animal data. Meta-analysis could be routinely conducted as part of the critical appraisal process when multiple suitable animal studies are available. Such meta-analyses would allow more informed decisions as to which therapeutics might advance to clinical trial.

Alternative pathway case studies: fluid management in sepsis
============================================================

As one case study exemplifying the proposed alternative pathway for preclinical research, a response to a RFP in the area of fluid management using colloids might characterize the proposed research as follows. First, the goal of this research is to determine if colloid therapy of sepsis ameliorates organ dysfunction, when administered in volumes that do not overwhelm the intravascular space. Second, while mortality is an important outcome for clinical trials of sepsis, organ dysfunction in animal models is an adequate surrogate. Finally, results from this study are to provide information for justification and design of clinical trials.

The proposal might then detail a set of hypotheses to be tested with use of two complementary animal models. It might, for instance, be hypothesized that colloid therapy will: (1) retard the progression of sepsis in sheep, as judged by reduction in tissue injury and gut translocation of endotoxin and improved circulatory reserve to a standardized hypoxic insult; (2) inhibit the progression of sepsis in rats, as evaluated by diminished myocardial, gut and renal dysfunction; and (3) reduce inflammation of the heart associated with sepsis in rats and sheep. Hypotheses (1) and (2) would be intended to satisfy the requirements of the RFP. Hypothesis (3) would address a potential mechanism of colloid action based upon prior evidence, such as the observation that fluid resuscitation can attenuate cytokine gene expression in experimental murine peritonitis \[[@B29]\]. The hypotheses, taken together, would both meet the needs of the RFP sponsor for data to justify and design clinical trials and address special research interests of the investigators submitting the proposal.

In evaluating the research proposal, it would be essential to ask how similar the animal models are to the clinical condition of interest. In a model of sepsis, for example, to what extent might the experimental animals conform to the established criteria for human sepsis? Perhaps fitting two or more of the following: temperature \>38 or \<36°C; heart rate \>90 beats/min; respiratory rate \>20 breaths/min or PaCO~2~ \<32 mmHg; and white blood cells \>12000 or \<4000 cells/mm^3^, or \>10% immature (band) forms \[[@B30]\]? Similarly, do the responses of the experimental animals to treatment resemble those anticipated in septic patients? Polymyxin-dextran anti-endotoxin pretreatment in an ovine model of normotensive sepsis produced an array of responses similar to those expected in patients, as shown in Table [3](#T3){ref-type="table"} \[[@B31]\]. This model would thus satisfy at least some of the criteria for appropriate preclinical evaluation of sepsis therapies.

###### 

Results of anti-endotoxin pretreatment in an ovine model of normotensive sepsis^\*^ \[[@B31]\]

  -----------------------------------------------------------
  Less pyrexia (*P* = 0.04)
  Higher mean arterial pressures (*P* = 0.02)
  Less variable serum albumin concentration (*P* = 0.05)
  Trend toward decreased lactate concentration (*P* = 0.10)
  -----------------------------------------------------------

^\*^48 h after randomization

The rigorousness of the study design would serve as another key criterion for evaluating the quality of the proposed research. The already described ovine model study was designed to address the hypothesis that, in sheep with sepsis induced by caecal ligation and perforation, pretreatment with polymyxin-dextran anti-endotoxin would be associated with fewer changes in microvascular integrity and cellular architecture in extrapulmonary organs \[[@B31]\]. The study was, importantly, a prospective double-blind, randomized trial, thus clearly conforming to the design requirements for definitive clinical trials.

The ovine model of sepsis has also been used to compare resuscitation fluids. This blinded study tested the hypothesis that type of fluid infused will modify both microvascular integrity and cellular structure in sepsis \[[@B32]\]. Sheep were randomized to receive crystalloid (Ringer\'s lactate) or colloid (pentastarch) for 48 h beginning 6 h after induction of experimental sepsis. Fluid was infused to maintain constant left atrial pressure. In order to maintain similar plasma volumes (Figure [2](#F2){ref-type="fig"}), it was necessary to infuse a significantly greater volume of crystalloid than colloid. Higher colloid osmotic pressure was achieved in the colloid recipients (Figure [2](#F2){ref-type="fig"}). These observations in the ovine model are consistent with those expected in patients. Moreover, fluid was titrated to achieve a target end diastolic filling pressure, and this mode of administration is typical of the fluid management approach taken in the clinical setting. The data in Figure [2](#F2){ref-type="fig"} also reveal that the randomized groups were comparable in baseline plasma volume and colloid osmotic pressure. Demonstration of the comparability of the study groups at baseline is also important in randomized clinical trials. While both groups attained a similar hyperdynamic circulatory response, the pentastarch group exhibited greater capillary luminal areas with less endothelial swelling and less parenchymal injury. This blinded randomized trial in an animal model thus provided evidence of benefit with a colloid used in a manner similar to that employed in patients.

![Effects of fluids in an ovine model of sepsis. **(a)** Plasma volume and **(b)** plasma osmotic pressure at baseline and 48 h in sheep with experimental sepsis receiving either pentastarch (black bars) or Ringer\'s lactate (white bars). Based on the data of Morisaki *et al* \[[@B32]\].](cc970-2){#F2}

Another case study involving blood or blood-substitute preparations demonstrates the application of animal studies in elucidating underlying physiologic mechanisms of clinical relevance. It has been shown that transfusion of older blood was associated with evidence of gastric mucosal ischemia in septic patients \[[@B33]\]. Red cell transfusion was also found ineffective for increasing splanchnic tissue oxygen utilization in septic patients as measured by gastric pHi \[[@B34]\]. These observations suggested that the age of transfused blood might be an important determinant of tissue oxygenation, and this possibility was assessed in a rodent model. Storage of rat red blood cells in this prospective randomized trial for 28 days impaired the ability to improve tissue oxygenation when transfused into either control or septic rats in a state of systemic oxygen uptake (VO~2~) supply dependency induced by isovolaemic haemodilution \[[@B35]\]. Similar observations have subsequently also been made in an ovine model.

The impaired oxygenation associated with stored blood may be a temporary phenomenon, since these blood cells may eventually undergo rejuvenation. Intravital video microscopy observations have indicated the occurrence of capillary dropout after transfusion of stored blood. Such dropout might be due to the increased rigidity of the stored cells, as well as, possibly, increased adhesion to endothelium. It is clear, in any case, that rigorously designed animal studies can have an important role to play in deducing physiologic mechanisms relevant to clinical fluid management.

Conclusion
==========

The fluid management landscape has been altered by recent meta-analyses, whatever their methodological limitations may have been. Yet important questions regarding optimal fluid management remain unanswered, and more research is needed. Experimental models that mimic, as faithfully as possible, a clinical condition of interest can make an important contribution. An alternative pathway of preclinical research might serve to reduce the risks and costs of developing therapies, thereby benefiting all participants in the healthcare system. Key elements of this pathway consist of hypotheses specified by developers of therapeutics, a competitive research process, randomized studies in clinically relevant animal models and critical appraisal, possibly including meta-analysis of animal data.

Commentary
==========

*Jean-Louis Vincent, MD, PhD:* Are not the data already reported on albumin administration in preclinical models sufficient? Much evidence has accumulated from the experimental studies of colloids as compared with crystalloids. What are the animal studies remaining to be done?

*William J Sibbald, MD:* That question can only be answered when framed very specifically in terms of the clinical condition of interest and the intended therapeutic intervention. In this context, it is not at all clear that all the relevant studies have already been performed.

*Andrew R Webb, MD:* Also, the quality of the available data should be considered. Much of what has been reported regarding colloids and crystalloids cannot be readily interpreted in terms of implications for clinical practice.

*Jean-Louis Vincent, MD, PhD:* Are there not also important limitations to the clinical questions that can be meaningfully addressed in animal models? For example, models of multiple organ failure are difficult to devise. Also, adult respiratory distress syndrome cannot easily be reproduced in animals.

*William J Sibbald, MD:* While there may be some limitations, the versatility of animal models in mimicking a broad range of clinical conditions should nevertheless be recognized.
